Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
University of Alabama, Birmingham, Alabama USC Norris Comprehensive Cancer Center, Los Angeles, California Sarah Cannon Research Institute - CO, Denver, Colorado Ochsner Clinic Foundation, New Orleans, Louisiana Beth Israel Deaconess Medical Center, Boston, Massachusetts START Midwest, Grand Rapids, Michigan Westchester Medical Center, Valhalla, New York Duke Universtiy, Durham, North Carolina OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma Sanford Cancer Center, Sioux Falls, South Dakota Fred Hutch Cancer Center, Seattle, Washington